Copyright Reports & Markets. All rights reserved.

Global Single-target Anti-VEGF Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Single-target Anti-VEGF Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Aflibercept
    • 1.3.3 Conbercept
    • 1.3.4 Ranibizumab
    • 1.3.5 Brolucizumab
    • 1.3.6 Faricimab
    • 1.3.7 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Single-target Anti-VEGF Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Age-related Macular Degeneration
    • 1.4.3 Diabetic Retinopathy
    • 1.4.4 Other
  • 1.5 Global Single-target Anti-VEGF Drugs Market Size & Forecast
    • 1.5.1 Global Single-target Anti-VEGF Drugs Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Single-target Anti-VEGF Drugs Sales Quantity (2021-2032)
    • 1.5.3 Global Single-target Anti-VEGF Drugs Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Roche
    • 2.1.1 Roche Details
    • 2.1.2 Roche Major Business
    • 2.1.3 Roche Single-target Anti-VEGF Drugs Product and Services
    • 2.1.4 Roche Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Roche Recent Developments/Updates
  • 2.2 Novartis
    • 2.2.1 Novartis Details
    • 2.2.2 Novartis Major Business
    • 2.2.3 Novartis Single-target Anti-VEGF Drugs Product and Services
    • 2.2.4 Novartis Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Novartis Recent Developments/Updates
  • 2.3 Coherus BioSciences
    • 2.3.1 Coherus BioSciences Details
    • 2.3.2 Coherus BioSciences Major Business
    • 2.3.3 Coherus BioSciences Single-target Anti-VEGF Drugs Product and Services
    • 2.3.4 Coherus BioSciences Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Coherus BioSciences Recent Developments/Updates
  • 2.4 Regeneron Pharmaceuticals
    • 2.4.1 Regeneron Pharmaceuticals Details
    • 2.4.2 Regeneron Pharmaceuticals Major Business
    • 2.4.3 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product and Services
    • 2.4.4 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Regeneron Pharmaceuticals Recent Developments/Updates
  • 2.5 Samsung Bioepis
    • 2.5.1 Samsung Bioepis Details
    • 2.5.2 Samsung Bioepis Major Business
    • 2.5.3 Samsung Bioepis Single-target Anti-VEGF Drugs Product and Services
    • 2.5.4 Samsung Bioepis Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Samsung Bioepis Recent Developments/Updates
  • 2.6 Biocon Biologics
    • 2.6.1 Biocon Biologics Details
    • 2.6.2 Biocon Biologics Major Business
    • 2.6.3 Biocon Biologics Single-target Anti-VEGF Drugs Product and Services
    • 2.6.4 Biocon Biologics Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Biocon Biologics Recent Developments/Updates
  • 2.7 Chengdu Kanghong Pharmaceutical
    • 2.7.1 Chengdu Kanghong Pharmaceutical Details
    • 2.7.2 Chengdu Kanghong Pharmaceutical Major Business
    • 2.7.3 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product and Services
    • 2.7.4 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates

3 Competitive Environment: Single-target Anti-VEGF Drugs by Manufacturer

  • 3.1 Global Single-target Anti-VEGF Drugs Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Single-target Anti-VEGF Drugs Revenue by Manufacturer (2021-2026)
  • 3.3 Global Single-target Anti-VEGF Drugs Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Single-target Anti-VEGF Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Single-target Anti-VEGF Drugs Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Single-target Anti-VEGF Drugs Manufacturer Market Share in 2025
  • 3.5 Single-target Anti-VEGF Drugs Market: Overall Company Footprint Analysis
    • 3.5.1 Single-target Anti-VEGF Drugs Market: Region Footprint
    • 3.5.2 Single-target Anti-VEGF Drugs Market: Company Product Type Footprint
    • 3.5.3 Single-target Anti-VEGF Drugs Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Single-target Anti-VEGF Drugs Market Size by Region
    • 4.1.1 Global Single-target Anti-VEGF Drugs Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Single-target Anti-VEGF Drugs Consumption Value by Region (2021-2032)
    • 4.1.3 Global Single-target Anti-VEGF Drugs Average Price by Region (2021-2032)
  • 4.2 North America Single-target Anti-VEGF Drugs Consumption Value (2021-2032)
  • 4.3 Europe Single-target Anti-VEGF Drugs Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Single-target Anti-VEGF Drugs Consumption Value (2021-2032)
  • 4.5 South America Single-target Anti-VEGF Drugs Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Single-target Anti-VEGF Drugs Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
  • 5.2 Global Single-target Anti-VEGF Drugs Consumption Value by Type (2021-2032)
  • 5.3 Global Single-target Anti-VEGF Drugs Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
  • 6.2 Global Single-target Anti-VEGF Drugs Consumption Value by Application (2021-2032)
  • 6.3 Global Single-target Anti-VEGF Drugs Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
  • 7.2 North America Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
  • 7.3 North America Single-target Anti-VEGF Drugs Market Size by Country
    • 7.3.1 North America Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
  • 8.2 Europe Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
  • 8.3 Europe Single-target Anti-VEGF Drugs Market Size by Country
    • 8.3.1 Europe Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Single-target Anti-VEGF Drugs Market Size by Region
    • 9.3.1 Asia-Pacific Single-target Anti-VEGF Drugs Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Single-target Anti-VEGF Drugs Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
  • 10.2 South America Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
  • 10.3 South America Single-target Anti-VEGF Drugs Market Size by Country
    • 10.3.1 South America Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Single-target Anti-VEGF Drugs Market Size by Country
    • 11.3.1 Middle East & Africa Single-target Anti-VEGF Drugs Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Single-target Anti-VEGF Drugs Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Single-target Anti-VEGF Drugs Market Drivers
  • 12.2 Single-target Anti-VEGF Drugs Market Restraints
  • 12.3 Single-target Anti-VEGF Drugs Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Single-target Anti-VEGF Drugs and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Single-target Anti-VEGF Drugs
  • 13.3 Single-target Anti-VEGF Drugs Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Single-target Anti-VEGF Drugs Typical Distributors
  • 14.3 Single-target Anti-VEGF Drugs Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Single-target Anti-VEGF Drugs market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Single-target anti-VEGF drugs are medications designed to specifically block the action of vascular endothelial growth factor(VEGF)in the eye.VEGF plays a crucial role in promoting the growth of abnormal blood vessels,which can lead to vision-threatening conditions such as wet age-related macular degeneration(AMD),diabetic retinopathy,and macular edema.
    This report is a detailed and comprehensive analysis for global Single-target Anti-VEGF Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Single-target Anti-VEGF Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Single-target Anti-VEGF Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Single-target Anti-VEGF Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Single-target Anti-VEGF Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Single-target Anti-VEGF Drugs
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Single-target Anti-VEGF Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Coherus BioSciences, Regeneron Pharmaceuticals, Samsung Bioepis, Biocon Biologics, Chengdu Kanghong Pharmaceutical, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Single-target Anti-VEGF Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Aflibercept
    Conbercept
    Ranibizumab
    Brolucizumab
    Faricimab
    Other
    Market segment by Application
    Age-related Macular Degeneration
    Diabetic Retinopathy
    Other
    Major players covered
    Roche
    Novartis
    Coherus BioSciences
    Regeneron Pharmaceuticals
    Samsung Bioepis
    Biocon Biologics
    Chengdu Kanghong Pharmaceutical
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Single-target Anti-VEGF Drugs product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Single-target Anti-VEGF Drugs, with price, sales quantity, revenue, and global market share of Single-target Anti-VEGF Drugs from 2021 to 2026.
    Chapter 3, the Single-target Anti-VEGF Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Single-target Anti-VEGF Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Single-target Anti-VEGF Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Single-target Anti-VEGF Drugs.
    Chapter 14 and 15, to describe Single-target Anti-VEGF Drugs sales channel, distributors, customers, research findings and conclusion.

    Buy now